Immune checkpoint inhibitors in esophageal cancer: Clinical development and perspectives.

Hum Vaccin Immunother · 2022 · PMC9746438 · PMID 36375821

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

However, non-prespecified subgroup analysis showed a trend of better median OS on pembrolizumab than on chemotherapy in patients with PD-L1-positive SCC (10.3 months vs. 6.7 months; HR 0.64, 95% CI 0.46–0.90).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.